IWWM-12 Poster A36 - A73 Abstracts

The following abstracts represent the poster presentations (A36-A73) given at IWWM-12 (Prague-2024)

Session Chairs: Andrew Branagan and Josephine Vos

A36: Medical resource utilization in patients with Waldenstrom's macroglobulinemia (WM) treated with zanubrutinib: First real-world results of the ARIADNE study from interim analysis 1 (IA 1} Jens Kisro

A37: Characterization of a novel dual HCK/BTK PROTAC (DFCl-002-06) that demonstrates potent in vitro activity and shows robust degradation of HCK and BTK in xenografted MYD88-mutated tumors in murine models Amanda Kofides

A38: In vitro Evaluation of a Novel Dual IRAK1/4 Degrader JH-Xlll-05-1 in the Treatment of B Cell Lymphomas Amanda Kofides

A39: Long Term Survival Outcomes of Allogeneic Haemopoietic Stem Cell Transplantation in Patients with Waldenstrom's Macroglobulinemia Charalampia Kyriakou

A40: Unbiased plasma proteomics in Waldenstrom Macroglobulinemia Pieter Langerhorst

A41: A Novel Waldenstrom's Macroglobulinemia Cell Line BCWM.2 Carrying a Rare MYD88 Mutation (p.Ser243Asn) with Unique Mutations and Suitability for In Vivo Xenograft Murine Model Shirong Liu

A42: Retrospective analysis of secondary AL amyloidosis in patients diagnosed with Waldenstrom Macroglobulinemia: a single-center experience Gianluca Maiorana

A43: Depth of response from fixed-duration treatment is associated with superior survival in Waldenstrom Macroglobulinemia Jonas Paludo

A44: Correlation Between Familial Waldenstrom Macroglobulinemia Clusters With Clinical Features, Complications, and Outcomes in 1000 Patients: A Single-Center Retrospective Cohort Study Andres Ramirez-Gamero

A45: Waldenstrom Macroglobulinemia and Blimp1 involvement in Double Strand Breaks and cell cycle Stamatia-Maria Rapti

A46: Population-based screening for lgM MGUS in Iceland: The iStopMM experience Saemundur Rognvaldsson

A47: Observational Retrospective Study Of The Treatment Of Waldenström's Macroglobulinemia With Ibrutinib In Routine Clinical Practice In Spain E. Rubio Azpeitia

A48: Dysregulation of microRNA in Waldenstrom macroglobulinemia Tereza Ruzickova

A49: Obinotuzumab Plus Bendamustine In Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia: The Experience Of One Center Viera Sandecka

A50: Waldenstrom's Macroglobulinemia: Clinical presentation & treatment outcome from a tertiary care centre from India Sanjeev Sanjeev

A51: Associations of Chromosomal Aberrations with Clinical Aggressiveness and Shorter Time to Next Treatment in Symptomatic Waldenstrom's Macroglobulinemia Naohiro Sekiguchi

A52: TRES Comorbidity Score Predicts Survival Outcomes in an International Cohort of Patients with Waldenstrom's Macroglobulinemia Geoffrey Shouse

A53: Molecular abnormalities in Waldenstrom's macroglobulincmia patients treated with rituximab, bortezomib, lenalidomide and dexamethasone: Whole exome sequencing analysis in KMM1803 study Gia-Young Song

A54: Second primary malignancies and disease transformation in symptomatic patients with Waldenstrom's Macroglobulinemia: Outcomes of a population-based analysis Vasiliki Spiliopoulou

A55: Prospective evaluation of minimal residual disease in patients with previously untreated Waldenstrom Macroglobulinemia (WM) undergoing treatment with Bendamustine, Rituximab and Acalabrutinib - a BRAWM study analysis Adam Suleman

A56: Harnessing Wearable Devices and Patient-Captured Outcomes for Subjective Health Monitoring in Waldenstrom Macroglobulinemia: A Longitudinal Remote Approach is Feasible Kim Summers

A57: Single-Cell Marrow Analysis Reveals Abnormal Activation of T Cells and Monocytes, Identifies CD35 as a New Biomarker in Waldenstrom Macroglobulinemia Hao Sun

A58: Assessment of Tumor Purity in CD19+ Sorted Cells from Waldenstrom Macroglobulinemia Patients and a Comparison of Data Integration Methods Using Neoplastic and Healthy Cell Annotation Ourania Theologi

A59: The Spectrum of lgM-Associated Peripheral Neuropathies - A Cohort Study from the Neurohaematology Clinic at Queen Square and UCLH  Oliver Tomkins

A60: A Case Series of Waldenstrom's Macroglobulinaemia and Multiple Myeloma Oliver Tomkins

A61: Bing-Neel Syndrome - A Case Series of 46 Patients from the United Kingdom Oliver Tomkins

A62: Development and Evaluation of a Multiplex Digital PCR Assay for Detecting CXCR4 S338X Mutations in Waldenstrom's Macroglobulinemia Nickolas Tsakmaklis

A63: Improving the Quality of Active Monitoring in Waldenstrom Macroglobulinemia: Results of a UK-Wide Patient-Centered Experience Survey and Proposed Standard of Care for Active Monitoring From a UK-Wide Patient-Expert Collaboration David Tucker

A64: Mapping Immune Regulators in the Tumor Microenvironment of Waldenstrom Macroglobulinemia Zuzana Valuskova

A65: The role of complement activation in IgM M-protein associated neuropathies J.P.M. van de Mortel

A66: Biochemical characterization of monoclonal lmmunoglobulin-M in Waldenstrom Macroglobulinemia  Wouter Verhaar

A67: Zanubrutinib in Light Chain Amyloidosis associated with Waldenstrom Macroglobulinemia and indolent B-cell lymphoma: tolerability and efficacy Wouter Verhaar

A68: Unraveling genetic heterogeneity of malignant and healthy cells in Waldenstrom Macroglobulinemia through integration of single-cell omics and whole-genome sequencing Christos Vlachos

A69: Zanubrutinib plus lxazomib & Dexamethasone in newly diagnosed symptomatic Waldenstrom macroglobulinemia:a phase II study Wenjie Xiong

A70: Phase II clinical study of Zanubrutinib combined with bendamustine and rituximab (ZBR) for time-limited treatment of Waldenstrom macroglobulinemia Wenjie Xiong

A71: Determination of MYD88 and CXCR4 mutation for clinical detection and their significance in Waldenstrom macroglobulinemia Ying Yu

A72: Lenalidomide and obinutuzumab in Patients with Relapsed/Refractory Waldenstrom macroglobulinemia Jingjing Yuan

A73: Scaffold Roles of IRAK1 and IRAK4 in Driving ERK1/2 Pro-Survival Signaling: A Rationale for Developing IRAK1/4 Degraders for the Treatment of Waldenström's Macroglobulinemia and MYD88-Mutated Lymphomas Xia Liu